| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
12,653,000 |
| Market
Cap: |
2.37(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.187 - $0.187 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kiora Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing products for treating disorders of the eye. Co.'s key product in clinical development is the EyeGate Ocular Bandage Gel, a topically applied eye drop formulation of modified hyaluronic acid (HA). HA is a naturally occurring polymer that is used in various physiological processes, including wound healing, hydration, tissue homeostasis, and joint lubrication. Co. modifies the HA through chemical cross-linking, which allows it to adhere to the ocular surface providing protection and lubrication for the treatment of corneal wounds, defects, and epitheliopathies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Goldberg Morton |
Director |
– • – |
2019-11-12 |
4 |
S |
$4.29 |
$8,584 |
D/D |
(2,001) |
1,961 |
|
- |
|
| Manzo Michael P. |
VP of Engineering |
• – – |
2019-11-05 |
4 |
D |
$3.86 |
$417 |
D/D |
(108) |
11,250 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2019-11-05 |
4 |
D |
$3.85 |
$412 |
D/D |
(107) |
11,227 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2019-11-05 |
4 |
D |
$3.85 |
$416 |
D/D |
(108) |
17,071 |
|
- |
|
| From Stephen |
President and CEO |
• • – |
2019-11-05 |
4 |
D |
$3.85 |
$2,580 |
D/D |
(670) |
66,296 |
|
- |
|
| From Stephen |
President and CEO |
• • – |
2019-10-09 |
4 |
D |
$2.95 |
$3,493 |
D/D |
(1,184) |
66,966 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2019-10-09 |
4 |
D |
$3.12 |
$574 |
D/D |
(184) |
11,334 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2019-10-09 |
4 |
D |
$3.10 |
$574 |
D/D |
(185) |
17,179 |
|
- |
|
| Manzo Michael P. |
VP of Engineering |
• – – |
2019-10-09 |
4 |
D |
$3.13 |
$579 |
D/D |
(185) |
11,358 |
|
- |
|
| Boyd Steven |
Director |
– • • |
2019-09-30 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
1,792,500 |
2.17 |
- |
|
| Boyd Steven |
Director |
– • • |
2019-09-30 |
4 |
B |
$3.11 |
$15,613 |
D/D |
5,001 |
1,792,500 |
3.92 |
- |
|
| Boyd Steven |
Director |
– • • |
2019-09-29 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
1,787,499 |
2.17 |
- |
|
| Boyd Steven |
Director |
– • • |
2019-09-29 |
4 |
B |
$3.13 |
$1,875,000 |
D/D |
600,000 |
1,787,499 |
3.92 |
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2019-08-06 |
4 |
D |
$0.21 |
$346 |
D/D |
(1,649) |
260,464 |
|
- |
|
| Wirostko Barbara |
Chief Medical Officer |
• – – |
2019-08-06 |
4 |
D |
$0.21 |
$345 |
D/D |
(1,641) |
403,893 |
|
- |
|
| From Stephen |
President and CEO |
• • – |
2019-08-06 |
4 |
D |
$0.21 |
$2,143 |
D/D |
(10,206) |
1,022,259 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2019-08-06 |
4 |
D |
$0.21 |
$345 |
D/D |
(1,641) |
172,783 |
|
- |
|
| Manzo Michael P. |
VP of Engineering |
• – – |
2019-08-06 |
4 |
D |
$0.21 |
$346 |
D/D |
(1,649) |
173,147 |
|
- |
|
| From Stephen |
President and CEO |
• • – |
2019-07-15 |
4 |
S |
$0.23 |
$9,891 |
D/D |
(42,452) |
1,032,465 |
|
- |
|
| Wirostko Barbara |
Chief Medical Officer |
• – – |
2019-07-15 |
4 |
S |
$0.23 |
$1,512 |
D/D |
(6,488) |
405,534 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2019-07-15 |
4 |
S |
$0.23 |
$1,480 |
D/D |
(6,350) |
174,424 |
|
- |
|
| Manzo Michael P. |
VP of Engineering |
• – – |
2019-07-15 |
4 |
S |
$0.23 |
$1,534 |
D/D |
(6,584) |
174,796 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2019-07-15 |
4 |
S |
$0.23 |
$1,534 |
D/D |
(6,584) |
262,113 |
|
- |
|
| From Stephen |
President and CEO |
• • – |
2019-07-12 |
4 |
S |
$0.24 |
$10,002 |
D/D |
(42,452) |
1,074,917 |
|
- |
|
| Wirostko Barbara |
Chief Medical Officer |
• – – |
2019-07-12 |
4 |
S |
$0.24 |
$1,529 |
D/D |
(6,488) |
412,022 |
|
- |
|
289 Records found
|
|
Page 6 of 12 |
|
|
